SCHEMBL3015128

SCHEMBL3015128

COc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cc(Br)ccc3OC)CC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.51
ALDH1A1 P00352 6/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
LMNA P02545 2/20 0.48
USP2 O75604 2/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 4/20 0.46
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MAPT P10636 2/20 0.43
RECQL P46063 2/20 0.43
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 3/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003923 0.93 GAA (0.49) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3645409 0.92 ALDH1A1 (0.44) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3006531 0.91 TP53 (0.41) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3012701 0.90 GAA (0.50) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3021724 0.90 GAA (0.52) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3017807 0.90 ALDH1A1 (0.61) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3008166 0.90 LMNA (0.54) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3010666 0.90 ALDH1A1 (0.48) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3022144 0.90 GAA (0.49) GAAALDH1A1L3MBTL1LMNAUSP2
SCHEMBL3015451 0.88 LMNA (0.42) GAAALDH1A1L3MBTL1LMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.